USA —In a bold move towards advancing laboratory diagnostics, Siemens Healthineers has obtained clearance from the US Food and Drug Administration for its cutting-edge analyzer, the Atellica CI.
Tailored for immunoassay and clinical chemistry testing in low- to medium-volume laboratories, this revolutionary instrument promises to set new standards in the field.
The Atellica CI Analyzer, formerly known as the Atellica CI 1900 in Europe, is designed to seamlessly integrate with Siemens’ flagship Atellica Solution instrument.
Utilizing the same reagents, consumables, and software, it provides a cohesive platform for a wide array of testing.
Siemens is set to offer an impressive menu of over 200 assays, covering 20 disease states. Among these, more than 50 key assays can deliver rapid results in less than 14 minutes, empowering healthcare professionals with timely and accurate information.
Beyond its speedy performance, the Atellica CI Analyzer boasts a compact 1.9-square-meter footprint, making it ideal for smaller laboratories.
Leveraging Microvolume Technology, this innovative instrument amplifies test output from a single sample aspiration.
Furthermore, Integrated Multi-sensor Technology (IMT) enables precise measurement of electrolytes in serum, plasma, and urine samples.
Features and functionality
The Atellica CI Analyzer is designed to enhance laboratory workflow and maintain clinical equivalence—a critical factor in a healthcare network.
Its random-access sampling, micro-volume aspiration, and automated maintenance and quality control scheduling ensure smooth and efficient operations.
Additionally, the instrument’s ability to generate reports to meet accreditation guidelines proves invaluable in maintaining high standards.
What sets the Atellica CI Analyzer apart is its capability to operate chemistry and immunoassay functions independently.
This feature prevents simultaneous interruptions, allowing laboratories to halt one function without disrupting the other. Such flexibility empowers labs to swiftly adapt to changing testing demands and optimize efficiency.
Sharon Bracken, head of diagnostics for Siemens Healthineers, expressed the significance of the Atellica CI Analyzer, stating, “This next-generation laboratory analyzer anticipates workflow bottlenecks, mitigates them proactively, and delivers insights based on data that help laboratory staff do their job more effectively and efficiently.”
With healthcare needs constantly evolving, this cutting-edge technology is poised to address challenges and pave the way for superior diagnostic solutions.
Immunoassay, as a highly selective and versatile bioanalytical technique, plays a pivotal role in the field of diagnostics and research.
By harnessing the power of antibodies or antigens as biorecognition agents, immunoassays have revolutionized our ability to detect and quantify a wide range of analytes, spanning from small molecules to complex macromolecules, in various biological samples.
The significance of robust immunoassay techniques cannot be overstated, as they underpin critical areas of medicine, including clinical diagnostics, pharmacology, and disease monitoring.
In clinical laboratories, immunoassays serve as indispensable tools for identifying specific proteins, hormones, drugs, and infectious agents, facilitating the early detection and accurate diagnosis of various diseases and health conditions.
Whether it’s monitoring blood glucose levels in diabetics, identifying infectious agents like viruses or bacteria, or measuring levels of cancer biomarkers, immunoassays have become the backbone of modern medical diagnostics.
Their sensitivity enables the quantification of analytes at minute concentrations, making immunoassays indispensable for detecting low-abundance molecules and monitoring subtle changes in biomarker levels over time.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
